Press Release: Cesca : Cesca Therapeutics' CAR-TXpress aims to 'dramatically' reduce manufacturing costs for CAR-T cells
Cesca Therapeutics (NASDAQ:KOOL) CEO Chris Xu sat down with Proactive at the 2019 BIO Investor Forum in New York. Cesca Therapeutics develops ......
Read full article »
Cesca develops and commercializes cell-based therapeutics for the treatment of immuno-oncology, vascular, cardiology and orthopedic diseases.
Read more